Eikon Therapeutics, Inc.

424B4 priced

Price $18.00 · 21,177,600 shares · Gross proceeds $381,196,800

Eikon Therapeutics, Inc. is conducting an initial public offering (IPO) of 21,177,600 shares of common stock at $18.00 per share, totaling $381,196,800. The shares will be listed on Nasdaq under the symbol 'EIKN.' This is the first public offering of the company's stock, with proceeds expected to be $354,513,024 after underwriting discounts. The company, an emerging growth company, has granted underwriters an option to purchase additional shares. The offering includes detailed financial terms, risk factors, and underwriting information.

CERT inactive

Eikon Therapeutics, Inc. filed a CERT (Correction/Amendment) on 2026-02-04, following an effectiveness notice for its S-1 registration statement on 2026-01-30. The current filing likely updates or corrects previously submitted IPO-related information, though specific details are obscured in the provided text.

EFFECT effective

Eikon Therapeutics, Inc. filed an S-1 registration statement effective January 30, 2026, transitioning from its previous 8-A12B filing. The S-1 confirms the effectiveness of the securities registration, enabling the company to commence trading on The Nasdaq Stock Market LLC. The filing references the prospectus and capital structure details from the S-1 registration statement, which was initially filed on January 9, 2026.

S-1/A amended

Range $16.00 to $18.00 · 17,648,000 shares

Eikon Therapeutics, Inc. is conducting an initial public offering (IPO) of 17,648,000 shares of common stock, with an estimated price range of $16.00 to $18.00 per share. The company, a late-stage biopharmaceutical firm focused on oncology, is advancing multiple clinical-stage product candidates, including EIK1001 (a TLR7/8 dual-agonist) and PARP inhibitors, targeting high-unmet-need cancers. The IPO follows a revised registration statement (S-1/A) with updated details on trials, underwriters, and risk factors. Eikon aims to list on Nasdaq under the symbol 'EIKN' and is an emerging growth company with a focus on integrating biology and engineering for faster drug development.

8-A12B effective

Eikon Therapeutics, Inc. is registering its common stock for listing on the Nasdaq Stock Market LLC, referencing the previously filed S-1 Registration Statement. The filing incorporates by reference the description of securities from the S-1, which outlines the company's initial public offering (IPO) details, including the registration of 17,648,000 shares, a price range of $16.00 to $18.00 per share, and underwriters such as J.P. Morgan and Morgan Stanley. The current 8-A12B form focuses on the registration process without additional material updates beyond the S-1/A.

S-1 filed

Eikon Therapeutics, Inc. is conducting an initial public offering (IPO) of its common stock, aiming to raise capital to advance its pipeline of biopharmaceutical candidates focused on oncology. The company, led by experienced executives including Dr. Roger M. Perlmutter (CEO) and Dr. Roy Baynes (CMO), is developing novel therapies targeting immuno-responsive cancers, DNA repair abnormalities, and hormonally responsive cancers. Key candidates include EIK1001 (a TLR7/8 dual-agonist) and EIK1005 (a WRN helicase inhibitor), with multiple clinical trials in progress. The IPO follows its designation as an emerging growth company and smaller reporting company, with shares expected to be listed on Nasdaq under the symbol 'EIKN'.

DRS/A amended

Eikon Therapeutics, Inc. is conducting an initial public offering (IPO) of its common stock, with an estimated price range and planned listing on Nasdaq under the symbol 'EIKN.' The company, focused on oncology, has multiple drug candidates in clinical trials, including EIK1001, a TLR7/8 dual-agonist, and others targeting DNA repair abnormalities and hormonally responsive cancers. The filing highlights risks related to clinical trial outcomes, regulatory approvals, and dependence on key leadership. The company is an emerging growth company with reduced reporting requirements.

DRS/A amended

Eikon Therapeutics, Inc. is conducting an initial public offering (IPO) of its common stock, aiming to list on a stock exchange under the symbol 'EIKN.' The company is a late-stage biopharmaceutical firm focused on developing innovative medicines for oncology, with multiple drug candidates in clinical trials. Key leadership includes Dr. Roger Perlmutter (CEO) and Dr. Roy Baynes (CMO), with underwriters J.P. Morgan and Morgan Stanley. The filing highlights ongoing trials for EIK1001, a TLR7/8 co-agonist, and other candidates targeting cancers with unmet needs.

DRS/A amended

Eikon Therapeutics, Inc. is preparing for its initial public offering (IPO) of common stock, aiming to raise capital to advance its pipeline of biopharmaceutical products. The company, led by experienced executives including Dr. Roger Perlmutter and Dr. Roy Baynes, focuses on oncology, with several drug candidates in clinical trials. The IPO is contingent on listing on a stock exchange, and the company has elected reduced reporting requirements as an emerging growth company. The filing includes details on the offering price range, underwriters (J.P. Morgan and Morgan Stanley), and risks related to clinical trials, regulatory approvals, and dependence on key personnel.

DRS filed

Eikon Therapeutics, Inc. is conducting its initial public offering (IPO) of common stock, aiming to raise capital for its late-stage biopharmaceutical development. The company focuses on oncology, with product candidates targeting immuno-responsive cancers, DNA repair abnormalities, and hormonally responsive cancers. Key candidates include EIK1001, a TLR7/8 co-agonist in Phase 2/3 trials, and EIK1003/EIK1004, selective PARP1 inhibitors. The IPO is led by underwriters J.P. Morgan and Morgan Stanley, with the company positioned as an emerging growth company.